Visão geral da empresa
A clinical-stage biopharmaceutical enterprise, Alzamend Neuro, Inc. is dedicated to the development of therapeutic solutions targeting neurodegenerative and psychiatric disorders. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which typically involves high capital expenditure and significant regulatory scrutiny before achieving commercial viability. As of the latest available data, the firm maintains a market capitalization of $3.43M and employs a workforce of 4 individuals. These valuation metrics and operational scale suggest that the company is in an early-stage development phase, characterized by limited revenue generation and a reliance on external capital to advance its pipeline, such as the AL001 product candidate.
Saúde financeira
The company reported annual revenue of N/A for the trailing twelve months, accompanied by a net income of $-7,544,730 and an EBITDA of $-6,939,160. The substantial disparity between the reported revenue figure and the significant negative net income highlights a cost structure where operational expenses far exceed current sales or where revenue recognition is deferred until later stages of clinical trials. Free cash flow stands at $-3,615,899, indicating that the company is burning through cash reserves to fund research and development activities rather than generating liquidity from operations. The balance sheet reflects a cash position of $2.71M contrasted against $0 in total debt, creating a scenario where the firm has no interest obligations but must manage its cash burn carefully. Margins across the board are reported as 0.0% for Gross Margin, Operating Margin, and Profit Margin, a common characteristic in clinical-stage biotechnology where the denominator (revenue) is negligible or non-existent relative to high fixed R&D costs. Return on Equity is calculated at -250.0%, while Return on Assets sits at -107.0%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than returns. The Current Ratio is recorded at 1.99, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, thereby maintaining a baseline of liquidity despite the negative earnings environment.
Avaliação de valorização
Valuation multiples for the company include a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the Forward P/E is reported at -0.35, a figure that reflects the expectation of continued negative earnings in the immediate future. The Price to Book ratio is 1.57, indicating that the market is pricing the company's equity at a premium of 57% over its book value, which can occur in biotech firms where the asset base (cash and IP) is valued higher than its historical cost. Alternative valuation metrics such as Price to Sales, which is N/A, and an EV/EBITDA of -0.10, provide limited traditional valuation context due to the company's lack of profitability and revenue history. Regarding trading range, the 52-Week High is $8.82 and the 52-Week Low is $0.90, placing the stock's current valuation in a context where it has experienced significant volatility relative to its historical trading bands. The Beta value is -0.05, an unusual statistic that implies the stock's price movement has historically moved inversely or with negligible correlation to the broader market, suggesting a unique risk profile distinct from standard sector peers.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both recorded as N/A, preventing a direct comparison of growth rates between the top line and bottom line as traditional metrics are unavailable for a company with minimal or no commercial sales. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that all available cash flow is theoretically available for reinvestment into the clinical pipeline rather than distribution to shareholders. Consequently, the firm follows a growth-at-all-costs strategy typical of early-stage biotechnology, where capital is retained to advance product candidates like AL001 rather than being distributed as income to investors. The overall growth and income profile is defined by a lack of current cash generation and dividend distribution, relying entirely on the potential future commercialization of its neurodegenerative and psychiatric disorder treatments to shift the financial trajectory.